Paul Tudor Jones Concert Pharmaceuticals, Inc. Transaction History

Tudor Investment Corp Et Al

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.27 - $7.2 $120,132 - $202,564	-28,134 Reduced 61.58%	17,554 $118,000
Q4 2021 Feb 14, 2022	SELL	$2.69 - $4.22 $91,847 - $144,087	-34,144 Reduced 42.77%	45,688 $144,000
Q3 2021 Nov 15, 2021	BUY	$3.17 - $4.15 $28,266 - $37,005	8,917 Added 12.57%	79,832 $261,000
Q2 2021 Aug 16, 2021	SELL	$3.77 - $5.24 $34,974 - $48,611	-9,277 Reduced 11.57%	70,915 $299,000
Q1 2021 May 17, 2021	BUY	$4.86 - $13.07 $389,733 - $1.05 Million	80,192 New	80,192 $400,000
Q4 2019 Feb 14, 2020	SELL	$5.71 - $9.22 $119,327 - $192,679	-20,898 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.88 - $12.35 $10,807 - $22,699	1,838 Added 9.64%	20,898 $123,000
Q2 2019 Aug 14, 2019	BUY	$9.44 - $13.12 $179,926 - $250,067	19,060 New	19,060 $229,000
Q2 2018 Aug 14, 2018	SELL	$16.83 - $21.66 $324,650 - $417,821	-19,290 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$19.24 - $28.03 $371,139 - $540,698	19,290 New	19,290 $442,000

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.